Angiodynamics Inc is a medical technology company that specializes in developing innovative solutions for vascular access, oncology, and the treatment of vascular diseases. The company focuses on creating advanced products for the minimally invasive treatment of various conditions, including cancer and vascular disorders. Angiodynamics integrates a range of devices, including catheters and radiosurgical platforms, with the aim of improving patient outcomes and enhancing the efficiency of healthcare providers. Through its commitment to research and development, Angiodynamics strives to deliver cutting-edge technologies that address unmet clinical needs in the healthcare sector. Read More
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:00 p.m. (PT).
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov. 10 2025.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&P 500 also rose, gaining, 0.07% to 6,715.87.
Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.
AngioDynamics (ANGO) beat Q1 FY2026 earnings and revenue estimates, driven by strong Med Tech growth. The company also raised its full-year financial outlook.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025.
